Table 4 Change in total cholesterol, triglyceride, HDL cholesterol, and Non-HDL cholesterol in 69 patients treated with Alirocumab 75 mg every 2 weeks (n = 29), or Alirocumab 150 mg (n = 18) or Evolocumab 140 mg (n = 22) every 2 weeks (ALI-EVO)
|  | Alirocumab 75 mg every 2 weeks (n = 29) Mean ± SD, median follow-up length 49 ± 13, 49 weeks | ALI-EVO (n = 40) Mean ± SD, median 37 ± 12, 33 weeks | |||||
|---|---|---|---|---|---|---|---|
Variable measured | percentile | percentile | |||||
25th | 50th | 75th | 25th | 50th | 75th | ||
Total cholesterol | Entry (mg/dl) | 172 | 192 | 230 | 224 | 255 | 288 |
Follow up (mg/dl) | 127 | 152 | 173 | 124 | 154 | 180 | |
Absolute change (mg/dl) | −14 | −54 | −95 | −71 | −105 | −132 | |
 P (paired Wilcoxon) | p < .0001 | p < .0001 | |||||
Percent change (%) | −6 | −26 | −38 | −35 | −39 | -49 | |
 P (Wilcoxon) | p < .0001 | p < .0001 | |||||
Triglyceride | Entry (mg/dl) | 96 | 130 | 184 | 129 | 161 | 233 |
Follow up (mg/dl) | 81 | 124 | 150 | 90 | 119 | 167 | |
Absolute change (mg/dl) | +7 | −12 | −53 | −1 | −47 | −102 | |
 P (paired Wilcoxon) | p = .060 | p < .0001 | |||||
Percent change (%) | +6 | −15 | −29 | −0.3 | −32 | -43 | |
 P (Wilcoxon) | p = .082 | p < .0001 | |||||
HDL cholesterol | Entry (mg/dl) | 40 | 51 | 61 | 42 | 50 | 58 |
Follow up (mg/dl) | 41 | 51 | 65 | 49 | 55 | 63 | |
Absolute change (mg/dl) | −4 | 0 | +7 | −1 | +5 | +10 | |
 P (paired Wilcoxon) | p = .40 | p = .0008 | |||||
Percent change (%) | −9 | 0 | +12 | −2 | +8 | +21 | |
 P (Wilcoxon) | p = .41 | p = .0002 | |||||
Non-HDL cholesterol | Entry (mg/dl) | 122 | 136 | 181 | 170 | 201 | 232 |
Follow up (mg/dl) | 25 | 50 | 75 | 70 | 92 | 121 | |
Absolute change (mg/dl) | −27 | −54 | −94 | −82 | −112 | −131 | |
 P (paired Wilcoxon) | p < .0001 | p < .0001 | |||||
Percent change (%) | −17 | −37 | −54 | −46 | −54 | -62 | |
 P (Wilcoxon) | p < .0001 | p < .0001 | |||||